News
News
Tepnel Gains Canadian IVD Approval of its Prenatal DNA Test for Chromosome Abnormalities
ELUCIGENE™ QST*R™ is a prenatal DNA-based diagnostic assay which detects common chromosome abnormalities.
News
TriPath Imaging Announces Receipt of BD Proposal
The proposal arose after a review by TriPath Imaging of potential strategic opportunities.
News
Tm Bioscience Completes Financing of Unsecured Subordinated Debentures and Warrants for Proceeds of $6.24 Million CDN
Proceeds from the financing will be used for the advancement of the Company's pipeline of genetic tests.
News
Digilab BioVisioN Continues Biomarker Cooperation with a Top 10 Pharmaceutical Company
Digilab BioVisioN and Novartis will continue and expand their cooperation in the field of biomarker discovery in drug treatment studies
News
The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease
PLSG has invested $100,000 in RedPath Integrated Pathology, Inc.
News
First-Ever Genomic Test Predicts which Lung Cancer Patients Need Chemotherapy to Live
Duke Scientists Develop Test which has the Potential to Save Tens of Thousands of Lives Each Year
News
AstraZeneca and The University of Manchester Work with DxS on a Clinical Pharmacology Collaboration
Research project aims to assess correlation between circulating DNA and primary tumours.
News
Tepnel Announces Extension of Supply Agreement of Cystic Fibrosis Screening Kits
French Cystic Fibrosis Screening Programme renews its agreement to purchase ELUCIGENE™ Mutation Detection Kits for a further three years.
News
Genomic Test to Predict which Lung Cancer Patients Need Chemotherapy to Live
Patients with early-stage non-small cell lung cancer will receive the genomic test and its results will determine their treatment.
News
Tepnel Life Sciences Trading Update
Tepnel’s results for the 6 months ended 30 June 2006 will reflect continued strong top line sales growth.
Advertisement
